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How	can	nanoparticles	be	used	in	sentinel	node	detection?	
      
Keywords:	 Sentinel	 node	biopsy	 (SNB);	 axillary	 staging;	 axillary	 surgery;	magnetic	 nanoparticles,	
multi-modal	probes;	antibody	labelling.	
 
Sentinel	 node	 biopsy	 (SNB)	 is	 the	 standard	 of	 care	 for	 axillary	 staging	 in	 breast	 cancer	 patients	
with	 a	 clinically	 and	 radiologically	 normal	 axilla.	 The	 concept	 is	 based	 upon	 the	 exclusion	 of	
metastases	 in	 the	 first	 draining	 lymph	 node(s)	 from	 the	 primary	 tumour.	 The	 current	 practice	
utilises	 a	 radiolabelled	 tracer	 and	 blue	 dye	 (combined	 technique)	 with	 reported	 sentinel	 node	
identification	 rates	 of	 96.4	 per	 cent,	 and	 a	 false	 negative	 rate	 of	 7.3	 per	 cent	 in	 a	 large	meta-
analysis.	 1	Although	successful,	 this	 technique	 is	 limited	by	 its	dependence	upon	 radioisotopes	 -	
with	 their	 inherent	 strict	 requirements	 for	 handling,	 transport,	 disposal,	 and	 close	 access	 to	
nuclear	medicine	facilities.	Blue	dye	is	also	associated	with	prolonged	skin	staining	and	reports	of	
anaphylaxis	 in	 0.9	 per	 cent	 of	 patients.	 2	 These	 limitations	 have	 resulted	 in	 the	 on-going	
development	of	alternative	techniques	for	SNB.	3,	4		
	
One	of	the	most	promising	radioisotope	independent	techniques	for	SNB	comprises	an	interstitial	
injection	 of	 superparamagnetic	 iron	 oxide	 (SPIO)	 nanoparticles,	 which	 are	 identified	 intra-
operatively	with	a	handheld	magnetometer	and	through	visual	brown-black	staining	of	nodes.	The	
magnetic	 technique	 has	 now	 been	 evaluated	 in	 a	 number	 of	 studies	 and	 confirmed	 on	 meta-
analysis	 to	 be	 non-inferior	 to	 the	 radioisotope-dependent	 technique	 in	 breast	 cancer	 -	 with	
sentinel	 node	 identification	 rates	 of	 97.1	 and	 96.8	 per	 cent	 respectively	 3	 –	 and	 demonstrated	
technical	benefits	over	other	novel	techniques.	4	The	non-inferiority	of	the	magnetic	technique	has	
	
	
2	
also	been	demonstrated	in	the	staging	of	malignant	melanoma	5	and	has	been	applied	to	a	range	
of	 solid	 cancers	 in	 small	 cohort	 series,	 which	 has	 demonstrated	 its	 feasibility	 in	 the	 staging	 of	
these	 malignancies.	 6-8	 What	 is	 still	 lacking	 is	 randomised	 controlled	 trial	 evidence,	 before	 the	
magnetic	technique	can	be	considered	as	an	alternative	to	the	standard	technique.	
	
The	 current	 trend	within	 axillary	management	 in	 breast	 cancer	 is	 towards	 quantification	 of	 the	
axillary	 metastatic	 burden.	 The	 identification	 of	 low	 axillary	 burden	 has	 been	 shown	 to	 allow	
avoidance	of	formal	axillary	node	clearance	(ANC),	without	compromising	overall	and	disease-free	
survival	 at	 long-term	 follow-up.	 9	 This	 evidence	 is	 leading	 to	 the	 concept	 of	 ‘selective	 axillary	
surgery’,	 which	would	 allow	 targeted	 excision	 of	 only	metastatically	 involved	 nodes.	 This	 relies	
upon	 improved	pre-operative	 imaging	 combined	with	novel	 techniques	 to	guide	 surgeons	 intra-
operatively,	 to	 involved	nodes.	Magnetic	 nanoparticles	have	been	used	 for	 axillary	 staging	non-
invasively	with	magnetic	resonance	 imaging	(MRI)	and	demonstrated	a	sensitivity	and	specificity	
for	 the	 detection	 of	 axillary	 involvement	 of	 98	 and	 96	 per	 cent	 respectively.	 10	 A	 limitation	 to	
implementation	of	this	approach	is	the	elevated	false	positive	rate	compared	to	SNB.	11	This	has	
led	to	the	development	of	dual	probes	to	allow	for	the	benefits	of	multi-modal	imaging.	Magnetic	
tracers	have	been	conjugated	with	radiolabelled	bisphosphonates	in	order	to	allow	simultaneous,	
excellent	anatomical	visualization	on	MRI	and	computerized	tomography	(CT)	scanning,	in	addition	
to	 functional	 categorization	 on	 positron-emission	 tomography	 (PET).	 12	 Triple-modal	 imaging	
magnetic	 nanocapsules,	 encapsulating	 hydrophobic	 SPIO	 to	 magnetically	 target	 solid	 tumours	
after	 intravenous	 administration	 has	 been	 developed.	 13	 Within	 a	 murine	 model	 the	 magnetic	
polymeric	nanocapsules	demonstrated	a	2-fold	increase	in	tumour	uptake	when	a	static	magnetic	
field	was	applied.	13	The	probes	allowed	fluorescence,	MRI	and	nuclear	imaging	to	be	performed,	
providing	 complementary	 information	 on	 the	 spatial	 distribution	 of	 the	 nanocarrier	 within	 the	
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tumour.	 Consequently,	multi-modal	 probes,	 which	 target	metastatic	 foci	 have	 been	 developed.	
These	have	included	fluorescent-ferrite	beads	containing	both	magnetic	iron	oxide	and	fluorescent	
europium	 complexes,	which	 have	 been	 labeled	with	 antibodies	 to	 a	 range	 of	 clinically	 relevant	
antigens	(BNP,	PSA,	EGFR,	CA19-9	and	HB-8509).	The	activation	of	these	particles	by	application	of	
a	magnetic	field	allows	for	immunohistochemical	staining	and	enhanced	intensity	of	fluorescence	
and	focal	quantification	of	antigen,	resulting	in	targeted	therapies	and	diagnostics.	14		
	
The	 use	 of	multimodal	 probes	 allows	 for	 optimization	 of	 pre-operative	 imaging	 to	 characterize	
lymph	 nodes	 and	 quantify	 nodal	 burden.	 The	 multimodal	 labelling	 also	 allows	 the	 surgeon	 to	
utilise	 different	 techniques	 to	 localise	 involved	 nodes	 and	 target	 them	 precisely.	 Open	 surgery	
could	 be	 directed	 with	 a	 handheld	 magnetometer	 to	 identify	 ‘hot	 spots’	 of	 magnetic	 tracer	
accumulation	 and	 hence	 metastatically	 involved	 nodes.	 Minimally	 invasive,	 percutaneous	
techniques	could	be	used	to	target	 the	magnetic	 tracer	accumulation	(nodes)	under	MRI-guided	
vision	and	excise	specimens	en	bloc.	Alternatively,	completely,	non-invasive	techniques	using	MRI-
guided	high	intensity	focused	ultrasound	(HIFU)	could	be	applied	to	the	same	targets	of	focal	iron	
accumulation	 and	 ablate	 the	 specimens	 without	 excision.	 This	 could	 equally	 be	 potentially	
achieved	 by	 the	 application	 of	 an	 alternating	 magnetic	 field	 to	 induce	 targeted	 magnetic	
hyperthermia.	
	
It	has	been	demonstrated	from	pre-clinical	porcine	models	15	that	only	2	per	cent	of	injected	SPIO	
reaches	 the	 draining	 sentinel	 nodes	 when	 the	 clinical	 volume	 of	 2	 mL	 (54	 mg	 iron	 oxide)	 of	
magnetic	tracer	is	injected	interstitially.	Consequently,	evidence	has	emerged	from	the	largest	trial	
of	the	magnetic	technique	that	this	retention	of	iron	can	produce	void	artefacts	on	MRI	and	that	in	
some	patients	this	can	be	prolonged.	16	This	area	requires	prospective	evaluation	to	confirm	these	
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findings	 but	 it	 is	 essential	 that	 on-going	 research	 attempt	 to	 reduce	 iron	 retention	 at	 injection	
sites.	The	injection	of	lower	volumes	(0.5	mL)	intra-tumorally	was	explored	clinically	but	resulted	
in	low	sentinel	node	identification	rates	compared	to	the	standard	combined	technique	(85	versus	
97	per	cent).	17	Porcine	models	demonstrated	a	significant	inverse	relationship	between	increasing	
injection	 volumes	 and	 percentage	 iron-uptake	 (relative	 to	 injected	 dose)	 by	 sentinel	 nodes	
(P<0.001).	 15	 Future	 work	 is	 needed	 to	 evaluate	 lower	 volume	 interstitial	 injections	 and	 the	
feasibility	of	intravenous	administration.	
	
The	 impact	of	 increasingly	 conservative	axillary	management	 in	breast	 cancer	has	 increased	 the	
importance	 of	 pre-operative	 staging	 using	 ultrasound.	 Trials	 are	 assessing	 whether	 a	 negative	
axilla	 on	 ultrasound	may	 eliminate	 the	 need	 for	 SNB	 completely.	 It	 is	 very	 likely	 that	 in	 future,	
pending	 the	 results	 of	 on-going	 trials,	 that	 the	 clinical	 indication	 for	 SNB	 may	 be	 reduced.	
However,	accurate	staging	will	 still	be	 required	 in	 those	patients	who	possess	an	abnormal	pre-
operative	 axillary	 ultrasound.	 This	 will	 be	 particularly	 the	 case	 in	 patients	 who	 are	 receiving	
primary	systemic	therapy	and	who	will	be	assessed	for	their	response	before	undergoing	definitive	
surgery.	 It	 has	 been	 shown	 that	 when	 this	 cohort	 of	 patients	 undergoes	 SNB,	 they	 have	 an	
elevated	false	negative	rate	 (12	per	cent),	which	 is	 lower	on	removal	of	3	or	more	nodes	 (9	per	
cent).	 18If	 the	 suspicious	 nodes	 are	 clipped	 at	 ultrasound	 and	 removed	 at	 SNB,	 then	 the	 false	
negative	 rate	 falls	 to	 less	 than	 2	 per	 cent.	 19	 The	 application	 of	 a	 solid	 ferromagnetic	marker	 –	
Introduced	 19,	 20	 into	 the	 suspicious	 nodes	 -	 which	 could	 subsequently	 be	 excised	 under	 intra-
operative	guidance	of	a	handheld	magnetometer,	would	be	clinically	relevant	and	avoid	technical	
and	 logistical	 difficulties	 associated	 with	 radioactive	 markers	 or	 wires.	 Both	 removal	 of	 more	
nodes	and	clipping	of	nodes	have	not	been	confirmed	in	subsequent	clinical	trials	as	yet.	
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The	use	of	SNB	is	in	an	advanced	stage	within	breast	cancer	compared	to	other	solid	cancers.	This	
has	 resulted	 in	 the	 emergence	 of	 the	 necessity	 to	 quantify	 axillary	 lymph	 node	 burden	 in	
determining	management	 rather	 than	 simply	 confirming	 the	 presence	 or	 absence	 of	metastatic	
involvement.	This	places	nanomedicine	 in	a	unique	position	to	allow	the	emergence	of	 targeted	
imaging	and	therapies.	These	therapies	will	allow	the	development	of	minimally	invasive,	selective	
axillary	surgery,	 targeting	metastatic	nodes	alone	and	provide	more	personalized	treatments	 for	
cancer	patients	of	the	future.	
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